AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18682741 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, clopidogrel, dipyridamole)
Number of subjects: 17
Study 18682741 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 17
Study 16484270 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 16484270 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 15853508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological interventions
Number of subjects: 0
Study 15853508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological interventions
Number of subjects: 0
Study 15853508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological and pharmacological interventions
Number of subjects: 0
Study 11300575 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level construals
Number of subjects: 0
Study 11300575 — intervention group
Group type: COMPARATOR
Intervention: High-level construals
Number of subjects: 0
Study 11300575 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased temporal distance
Number of subjects: 0
Study 11300575 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversion to inconvenience
Number of subjects: 0
Study 11300575 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-avoidance conflict
Number of subjects: 0
Study 9391254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous octreotide (50 pg/h for 48 hours)
Number of subjects: 150
Study 9391254 — intervention group
Group type: COMPARATOR
Intervention: Emergency sclerotherapy
Number of subjects: 150
Study 9391254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous octreotide
Number of subjects: 150
Study 7944837 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin levels in the highest quartile at baseline (younger-onset group)
Number of subjects: 1516
Study 7944837 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin levels in the highest quartile at baseline (older-onset group taking insulin)
Number of subjects: 1516
Study 7944837 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin levels in the highest quartile at baseline (older-onset group not taking insulin)
Number of subjects: 1516
Study 3266255 — intervention group
Group type: EXPERIMENTAL
Intervention: Social influences model program taught by peer leaders and teachers
Number of subjects: 0
Study 3266255 — intervention group
Group type: COMPARATOR
Intervention: Health consequences program
Number of subjects: 0
Study 3266255 — intervention group
Group type: COMPARATOR
Intervention: Existing-curriculum condition
Number of subjects: 0
Study 28643427 — intervention group
Group type: EXPERIMENTAL
Intervention: PVR after uroflowmetry
Number of subjects: 77
Study 28643427 — intervention group
Group type: EXPERIMENTAL
Intervention: PVR after uroflowmetry and random PVR divided into three groups
Number of subjects: 77
Study 28643427 — intervention group
Group type: EXPERIMENTAL
Intervention: PVR after uroflowmetry in patients with bladder capacity >400 mL
Number of subjects: 77
Study 28643427 — intervention group
Group type: EXPERIMENTAL
Intervention: Random PVR in patients with bladder capacity >400 mL
Number of subjects: 77
Study 27378812 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle-separated environment (PSE)
Number of subjects: 11
Study 27378812 — intervention group
Group type: COMPARATOR
Intervention: Conventional environment (CE)
Number of subjects: 11
Study 25032805 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate group <70 beats per minute
Number of subjects: 160
Study 25032805 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate group 70-79 beats per minute
Number of subjects: 160
Study 25032805 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate group 80-89 beats per minute
Number of subjects: 160
Study 25032805 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate group ≥90 beats per minute
Number of subjects: 160
Study 25032805 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight subjects
Number of subjects: 160
Study 25032805 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight subjects
Number of subjects: 160
Study 25032805 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects
Number of subjects: 160
Study 24066743 — intervention group
Group type: EXPERIMENTAL
Intervention: CMX001 (100 mg twice weekly)
Number of subjects: 230
Study 24066743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 24066743 — intervention group
Group type: EXPERIMENTAL
Intervention: CMX001 (200 mg weekly or higher)
Number of subjects: 230
Study 24066743 — intervention group
Group type: EXPERIMENTAL
Intervention: CMX001 (200 mg twice weekly)
Number of subjects: 230
Study 19773749 — intervention group
Group type: EXPERIMENTAL
Intervention: Flushknife (endo-knife with water-jet function)
Number of subjects: 49
Study 19773749 — intervention group
Group type: COMPARATOR
Intervention: Flexknife (electrosurgical endo-knife without water-jet function)
Number of subjects: 49
Study 17394563 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg twice daily)
Number of subjects: 0
Study 17394563 — intervention group
Group type: COMPARATOR
Intervention: Metformin (850 mg twice daily)
Number of subjects: 0
Study 16635226 — intervention group
Group type: EXPERIMENTAL
Intervention: Motilin (300 ng/kg/30 min i.v.)
Number of subjects: 21
Study 16635226 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (12 microg/kg/h) with motilin
Number of subjects: 21
Study 16635226 — intervention group
Group type: COMPARATOR
Intervention: Atropine alone
Number of subjects: 21
Study 16635226 — intervention group
Group type: EXPERIMENTAL
Intervention: Motilin infusion
Number of subjects: 21
Study 12705362 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine 8-10 microg/kg/day in newborns
Number of subjects: 34
Study 12705362 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine 15 microg/kg/day in infants
Number of subjects: 34
Study 12705362 — intervention group
Group type: COMPARATOR
Intervention: Untreated hyperthyroid adults
Number of subjects: 34
Study 12705362 — intervention group
Group type: COMPARATOR
Intervention: Controls (not specified)
Number of subjects: 34
Study 12705362 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroid newborns at diagnosis
Number of subjects: 34
Study 12705362 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroid infants at diagnosis
Number of subjects: 34
Study 10626716 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS unit
Number of subjects: 40
Study 10626716 — intervention group
Group type: COMPARATOR
Intervention: Inactive TENS unit
Number of subjects: 40
Study 10626716 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TENS on and TENS off)
Number of subjects: 40
Study 9174876 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized heparin inhalation (1,000 U/kg)
Number of subjects: 15
Study 9174876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1605988 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback and pelvic floor exercises
Number of subjects: 135
Study 1605988 — intervention group
Group type: COMPARATOR
Intervention: Mixed incontinence (MI) group
Number of subjects: 135
Study 3522407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (single oral 2 g dose)
Number of subjects: 79
Study 3522407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 29758184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral voriconazole
Number of subjects: 194
Study 29758184 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 194
Study 29758184 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 194
Study 27197020 — intervention group
Group type: EXPERIMENTAL
Intervention: Single screw-rod anterior instrumentation (SSRAI)
Number of subjects: 51
Study 27197020 — intervention group
Group type: EXPERIMENTAL
Intervention: Double screw-rod anterior instrumentation (DSRAI)
Number of subjects: 51
Study 25111123 — intervention group
Group type: COMPARATOR
Intervention: Glucose beverage
Number of subjects: 24
Study 25111123 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose beverage
Number of subjects: 24
Study 23894797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality Salience (MS)
Number of subjects: 62
Study 23894797 — intervention group
Group type: COMPARATOR
Intervention: Non-Mortality Salience (non-MS)
Number of subjects: 62
Study 23894797 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational conceptual mode
Number of subjects: 62
Study 23894797 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential conceptual mode
Number of subjects: 62
Study 19815369 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program for patients receiving VKAs, including individual sessions, telephone support, group sessions, and educational tools.
Number of subjects: 0
Study 17515687 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (AR)
Number of subjects: 10
Study 17515687 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 10
Study 17515687 — intervention group
Group type: COMPARATOR
Intervention: Stretching (ST)
Number of subjects: 10
Study 15347426 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention tailored to improve pharmacological management of hypertension and hypercholesterolaemia
Number of subjects: 0
Study 15347426 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11229858 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 0
Study 11229858 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol
Number of subjects: 0
Study 11229858 — intervention group
Group type: COMPARATOR
Intervention: Antipyretic treatment
Number of subjects: 0
Study 9653015 — intervention group
Group type: COMPARATOR
Intervention: HLA-DRB1*0701
Number of subjects: 39
Study 9653015 — intervention group
Group type: COMPARATOR
Intervention: HLA-DQB1*0201
Number of subjects: 39
Study 9653015 — intervention group
Group type: COMPARATOR
Intervention: HLA-DPB1*1601
Number of subjects: 39
Study 8281625 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 20 mg
Number of subjects: 30
Study 8281625 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg
Number of subjects: 30
Study 8281625 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg
Number of subjects: 30
Study 8281625 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 200 mg
Number of subjects: 30
Study 8281625 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 300 mg
Number of subjects: 30
Study 2912024 — intervention group
Group type: EXPERIMENTAL
Intervention: vindesine 3 mg/m2 weekly
Number of subjects: 54
Study 2912024 — intervention group
Group type: EXPERIMENTAL
Intervention: spirogermanium 80 mg/m2 three times weekly (escalated to 120 mg/m2)
Number of subjects: 54
Study 2912024 — intervention group
Group type: EXPERIMENTAL
Intervention: spirogermanium
Number of subjects: 54
Study 2912024 — intervention group
Group type: EXPERIMENTAL
Intervention: vindesine
Number of subjects: 54
Study 1155056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin plus nasal decongestant
Number of subjects: 300
Study 1155056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin plus irrigation
Number of subjects: 300
Study 1155056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine plus nasal decongestant
Number of subjects: 300
Study 1155056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine plus irrigation
Number of subjects: 300
Study 1155056 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycinestolate plus nasal decongestant
Number of subjects: 300
Study 1155056 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycinestolate plus irrigation
Number of subjects: 300
Study 1155056 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study 30367891 — intervention group
Group type: EXPERIMENTAL
Intervention: Raisins near (20 cm), M&Ms far (70 cm)
Number of subjects: 248
Study 30367891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both foods near
Number of subjects: 248
Study 30367891 — intervention group
Group type: EXPERIMENTAL
Intervention: M&Ms near, raisins far
Number of subjects: 248
Study 30367891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both far
Number of subjects: 248
Study 30367891 — intervention group
Group type: EXPERIMENTAL
Intervention: M&Ms near
Number of subjects: 248
Study 28768173 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0090-2746 (1.8 mg subcutaneously once daily)
Number of subjects: 0
Study 28768173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28768173 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg subcutaneously once daily)
Number of subjects: 0
Study 25358038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-similarity character with severe depression
Number of subjects: 80
Study 25358038 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-similarity character with severe depression
Number of subjects: 80
Study 25358038 — intervention group
Group type: COMPARATOR
Intervention: Control group (no article)
Number of subjects: 80
Study 24254035 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (12 sessions, 3 times/week for 1 month, using TENS acupuncture pen at ST-36, GB-34, SP-6, K-1 points)
Number of subjects: 118
Study 24254035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupressure treatment)
Number of subjects: 118
Study 21300382 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose
Number of subjects: 115
Study 21300382 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 115
Study 19997797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of cefmetazol on the day of surgery (group 1)
Number of subjects: 275
Study 19997797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of cefotiam for 3 days (group 2)
Number of subjects: 275
Study 22524979 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen (OFIRMEV(®); 1,000 mg, 15 minute infusion)
Number of subjects: 6
Study 22524979 — intervention group
Group type: EXPERIMENTAL
Intervention: PO acetaminophen (2 Tylenol(®) 500 mg caplets)
Number of subjects: 6
Study 22524979 — intervention group
Group type: EXPERIMENTAL
Intervention: PR acetaminophen (2 Feverall(®) 650 mg suppositories)
Number of subjects: 6
Study 17356929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (4 mg)
Number of subjects: 16
Study 17356929 — intervention group
Group type: COMPARATOR
Intervention: Control group (macular focal and grid laser photocoagulation)
Number of subjects: 16
Study 12842371 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-IPV or IPV after HTMV
Number of subjects: 2000
Study 12842371 — intervention group
Group type: COMPARATOR
Intervention: Standard measles vaccine (control)
Number of subjects: 2000
Study 12842371 — intervention group
Group type: EXPERIMENTAL
Intervention: HTMV without additional DTP-IPV or IPV
Number of subjects: 2000
Study 12842371 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-IPV after routine HTMV
Number of subjects: 2000
Study 12842371 — intervention group
Group type: EXPERIMENTAL
Intervention: No DTP-IPV after routine HTMV
Number of subjects: 2000
Study 12842371 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP or IPV after HTMV (combined results)
Number of subjects: 2000
Study 12842371 — intervention group
Group type: EXPERIMENTAL
Intervention: No DTP or IPV after HTMV (combined results)
Number of subjects: 2000
Study 10471182 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaxigrip injection
Number of subjects: 1356
Study 7794571 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril
Number of subjects: 17
Study 7794571 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 17
Study 2190758 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dermatologic patch (Actiderm) plus topical beta‐methasone valerate 0.1 percent cream
Number of subjects: 0
Study 2190758 — intervention group
Group type: COMPARATOR
Intervention: Topical beta‐methasone valerate 0.1 percent cream alone
Number of subjects: 0
Study 2190758 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dermatologic patch (Actiderm) alone
Number of subjects: 0
Study 380386 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined electrostimulation-hypalgesia with nitrous-oxide oxygen mixture
Number of subjects: 30
Study 380386 — intervention group
Group type: COMPARATOR
Intervention: Nitrous-oxide and oxygen mixture only (Control)
Number of subjects: 30
Study 31955942 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app-based self-management program
Number of subjects: 44
Study 31955942 — intervention group
Group type: COMPARATOR
Intervention: Control group (one call a month from research staff)
Number of subjects: 44
Study 29143122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (3200 IU/day for 5 weeks)
Number of subjects: 3
Study 29143122 — intervention group
Group type: COMPARATOR
Intervention: Placebo with normal concentration of vitamin D (SUF)
Number of subjects: 3
Study 29143122 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with vitamin D deficiency (DEF)
Number of subjects: 3
Study 27265887 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy nurse (EN) group
Number of subjects: 187
Study 27265887 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 187
Study 27252754 — intervention group
Group type: EXPERIMENTAL
Intervention: Fifth generation bonding agent
Number of subjects: 64
Study 27252754 — intervention group
Group type: EXPERIMENTAL
Intervention: Seventh generation bonding agent
Number of subjects: 64
Study 27252754 — intervention group
Group type: COMPARATOR
Intervention: Sealant alone
Number of subjects: 64
Study 23945138 — intervention group
Group type: EXPERIMENTAL
Intervention: WalkLink+: prompted and provided feedback on participants' online and in‐person social‐network interactions to expand networks for PA, plus provided evidence‐based online walking program and weekly walking tips
Number of subjects: 308
Study 23945138 — intervention group
Group type: EXPERIMENTAL
Intervention: WalkLink: evidence‐based online walking program and weekly tips only
Number of subjects: 308
Study 23945138 — intervention group
Group type: COMPARATOR
Intervention: Minimal Treatment Control: weekly tips only
Number of subjects: 308
Study 20584793 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection plus exercise
Number of subjects: 232
Study 20584793 — intervention group
Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 232
Study 18622144 — intervention group
Group type: EXPERIMENTAL
Intervention: F13B His95Arg variant in patients with LVD
Number of subjects: 887
Study 18622144 — intervention group
Group type: COMPARATOR
Intervention: None of the 21 other prothrombotic gene variants
Number of subjects: 887
Study 16860068 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue directed biopsies (MBDB)
Number of subjects: 30
Study 16860068 — intervention group
Group type: COMPARATOR
Intervention: Random 4 quadrant biopsies (RB)
Number of subjects: 30
Study 12816306 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF)
Number of subjects: 91
Study 12816306 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelial free gingival graft (EFGG)
Number of subjects: 91
Study 12816306 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue graft (CTG)
Number of subjects: 91
Study 12816306 — intervention group
Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 91
Study 10971105 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 IU/kg per week subcutaneous recombinant human GH
Number of subjects: 145
Study 10971105 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 IU/kg per week subcutaneous recombinant human GH
Number of subjects: 145
Study 10971105 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of GH
Number of subjects: 145
Study 8569467 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (CS) + oral cyclophosphamide (CYC) + plasma exchanges (PE)
Number of subjects: 342
Study 8569467 — intervention group
Group type: COMPARATOR
Intervention: CS + PE
Number of subjects: 342
Study 8569467 — intervention group
Group type: EXPERIMENTAL
Intervention: CS + oral CY
Number of subjects: 342
Study 8569467 — intervention group
Group type: EXPERIMENTAL
Intervention: CS + pulse CY + PE
Number of subjects: 342
Study 8569467 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-factors score (FFS)
Number of subjects: 342
Study 1379376 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 5
Study 1379376 — intervention group
Group type: COMPARATOR
Intervention: rhEpo
Number of subjects: 5
Study 6352967 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care instructions and health education program provided to families (intervention group)
Number of subjects: 433
Study 6352967 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 433
Study 31952938 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (5 × 10^9 cfu/capsule)
Number of subjects: 80
Study 31952938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 29894491 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Life Support (BLS) attempts initiation
Number of subjects: 501
Study 29894491 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to perform CPR
Number of subjects: 501
Study 29894491 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to use an AED device
Number of subjects: 501
Study 29894491 — intervention group
Group type: COMPARATOR
Intervention: Willingness to initiate BLS attempts by gender
Number of subjects: 501
Study 29894491 — intervention group
Group type: COMPARATOR
Intervention: Willingness to use an AED device by gender
Number of subjects: 501
Study 29894491 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and willingness for BLS attempts by age
Number of subjects: 501
Study 29894491 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and willingness for AED use by age
Number of subjects: 501
Study 27214145 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled, nebulized AZD5423 at doses of at least 300 μg for 2 weeks
Number of subjects: 0